This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Today's Health Winners and Losers

Looking ahead, Kensey Nash sees third-quarter earnings of 13 cents to 15 cents a share, or 19 cents to 21 cents a share before items. Net sales, meanwhile, are expected to be between $9 million and $9.5 million, while royalties are projected at $5.8 million to $6 million. Analysts project earnings of 23 cents a share on total sales, which includes net sales and royalties, of $17.2 million. Shares were down $1.34 to $24.94.

Shares of Schering-Plough (SGP) fell 2% after the drugmaker posted fourth-quarter results that fell below expectations. The company earned $104 million, or 7 cents a share, on sales of $2.32 billion. Analysts expected earnings of 8 cents a share and sales of $2.39 billion. During the year-earlier quarter, the company posted a loss of $856 million, or 58 cents a share, on sales of $2.18 billion. Last year's loss included a tax charge of $807 million, or 55 cents a share, related to the repatriation of foreign earnings. Shares were trading down 38 cents to $19.70.

Shares of Misonix (MSON) jumped 57% after the medical-device maker received Food and Drug Administration clearance to market and sell its Sonatherm 600 product in the U.S. The product is used for removing soft tissue lesions during surgical procedures. The product, which will first be launched in areas outside of the U.S., should be ready for the U.S. market around 2007 or 2008, the company said. Shares were trading up $2.61 to $7.17.

CombinatoRx (CRXX) gained 18% after the biopharmaceutical company's osteoarthritis drug showed positive results in a phase II clinical trial. CombinatoRx said the trial met its endpoint of reducing pain by a statistically significant amount when compared to a placebo. The drug was well tolerated and there were no serious adverse events reported, the company said. "We look forward to completing the secondary analyses, presenting the data in an appropriate medical forum, and finalizing our further development plans for this product candidate," the company said. Shares were up $1.89 to $12.50.

Other health care volume movers included Pfizer (PFE), up 9 cents to $26.08; Boston Scientific (BSX), down 44 cents to $21.19; Johnson & Johnson (JNJ), down 41 cents to $58.30; Amgen (AMGN), up $1.26 to $72.57; NMT Medical (NMTI), up $4.66 to $21.92; Genta (GNTA), up 19 cents to $2.39; Nektar Therapeutics (NKTR), down $1.04 to $19.71; Guidant (GDT), down 79 cents to $72.93; Bristol-Myers Squibb (BMY), down 12 cents to $22.87; Merck (MRK), down 61 cents to $34.09; Teva Pharmaceutical Industries (TEVA), up 76 cents to $42.06; and Elan (ELN), up 7 cents to $14.62.

2 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,098.45 +18.88 0.11%
S&P 500 2,003.37 +6.63 0.33%
NASDAQ 4,580.2710 +22.5760 0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs